Association between obstructive sleep apnoea and cancer: a cross-sectional, population-based study of the DISCOVERY cohort. Issue 3 (3rd March 2023)

• Record Type: Journal Article
• Authors: Palm, Andreas; Theorell-Haglöw, J; Isakson, Johan; Ljunggren, Mirjam; Sundh, Josefin; Ekström, Magnus Per; Grote, Ludger
• Is Part Of: BMJ open. Volume 13:Issue 3(2023)
• Publication Date: 2023-03-03
• Subjects: SLEEP MEDICINE -- ONCOLOGY -- Adult thoracic medicine; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-064501
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: Nocturnal hypoxia in obstructive sleep apnoea (OSA) is a potential risk factor for cancer. We aimed to investigate the association between OSA measures and cancer prevalence in a large national patient cohort. Design: Cross-sectional study. Settings: 44 sleep centres in Sweden. Participants: 62 811 patients from the Swedish registry for positive airway pressure (PAP) treatment in OSA, linked to the national cancer registry and national socioeconomic data (the course of DIsease in patients reported to Swedish CPAP, Oxygen and VEntilator RegistrY cohort). Outcome measures: After propensity score matching for relevant confounders (anthropometric data, comorbidities, socioeconomic status, smoking prevalence), sleep apnoea severity, measured as Apnoea-Hypopnoea Index (AHI) or Oxygen Desaturation Index (ODI), were compared between those with and without cancer diagnosis up to 5 years prior to PAP initiation. Subgroup analysis for cancer subtype was performed. Results: OSA patients with cancer (n=2093) (29.8% females, age 65.3 (SD 10.1) years, body mass index 30 (IQR 27–34) kg/m 2 ) had higher median AHI (n/hour) (32 (IQR 20–50) vs 30 (IQR 19–45), n/hour, p=0.002) and median ODI (n/hour) (28 (IQR 17–46) vs 26 (IQR 16–41), p<0.001) when compared with matched OSA patients without cancer. In subgroup analysis, ODI was significantly higher in OSA patients with lung cancer (N=57; 38 (21–61) vs 27 (16-43), p=0.012)), prostate cancer (N=617; 28 (17–46) vs 24, (16–39)p=0.005) and malignant melanoma (N=170; 32 (17–46) vs 25 (14–41), p=0.015). Conclusions: OSA mediated intermittent hypoxia was independently associated with cancer prevalence in this large, national cohort. Future longitudinal studies are warranted to study the potential protective influence of OSA treatment on cancer incidence.